相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors
Elena Gonzalez-Rodriguez et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Bone Mineral Density After Transitioning From Denosumab to Alendronate
David Kendler et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains
Judith Everts-Graber et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2020)
Ten Years of Very Infrequent Zoledronate Therapy in Older Women: An Open-Label Extension of a Randomized Trial
Andrew Grey et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang et al.
LANCET (2020)
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial
Robert Coleman et al.
LANCET ONCOLOGY (2020)
Hematological findings and complications of COVID-19
Evangelos Terpos et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
The Untold Toll - The Pandemic's Effects on Patients without Covid-19
Lisa Rosenbaum
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Administration of teriparatide for four years cyclically compared to two years daily in treatment Naive and alendronate treated women
Felicia Cosman et al.
BONE (2019)
Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial
Kenneth G. Saag et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial
Athanasios D. Anastasilakis et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial
Benjamin Z. Leder et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab
D. L. Kendler et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports
O. Lamy et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension
Steven R. Cummings et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting
Arthur N. Lau et al.
JOURNAL OF RHEUMATOLOGY (2018)
Screening for Osteoporosis to Prevent Fractures US Preventive Services Task Force Recommendation Statement
Susan J. Curry et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study
Michael R. McClung et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Fracture Prevention with Zoledronate in Older Women with Osteopenia
Ian R. Reid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
Bente L. Langdahl et al.
LANCET (2017)
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Kenneth G. Saag et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
Henry G. Bone et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE
Rhoda H. Cobin et al.
ENDOCRINE PRACTICE (2017)
Bone Loss After Denosumab: Only Partial Protection with Zoledronate
Ian R. Reid et al.
CALCIFIED TISSUE INTERNATIONAL (2017)
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
Alison T. Stopeck et al.
SUPPORTIVE CARE IN CANCER (2016)
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
F. Cosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate
Felicia Cosman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
Benjamin Z. Leder et al.
LANCET (2015)
Risk of Hospitalized Infection Among Rheumatoid Arthritis Patients Concurrently Treated With a Biologic Agent and Denosumab
Jeffrey R. Curtis et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Five years of anti-resorptive activity after a single dose of zoledronate - Results from a randomized double-blind placebo-controlled trial
Andrew Grey et al.
BONE (2012)
A single-dose study of denosumab in patients with various degrees of renal impairment
Geoffrey A. Block et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
Dennis M. Black et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women
N. Freemantle et al.
OSTEOPOROSIS INTERNATIONAL (2012)
The Adverse Effects of Estrogen and Selective Estrogen Receptor Modulators on Hemostasis and Thrombosis
Arturo Artero et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2012)
Effect of Stopping Risedronate after Long-Term Treatment on Bone Turnover
Richard Eastell et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial
Paul D. Miller et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
Henry G. Bone et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Efficacy of Continued Alendronate for Fractures in Women With and Without Prevalent Vertebral Fracture: The FLEX Trial
Ann V. Schwartz et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
FRAX (R) and its applications to clinical practice
John A. Kanis et al.
BONE (2009)
Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent
Felicia Cosman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Effects of Teriparatide Treatment and Discontinuation in Postmenopausal Women and Eugonadal Men with Osteoporosis
Benjamin Z. Leder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro
Zachary J. Henneman et al.
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A (2008)
Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis
Steven Boonen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Fracture risk remains reduced one year after discontinuation of risedronate
N. B. Watts et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Oral ibandronate in the management of postmenopausal osteoporosis: Review of upper gastrointestinal safety
S Epstein et al.
MATURITAS (2006)
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis
DM Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate
B Ettinger et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
The importance of bisphosphonate therapy mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]
ES Kurland et al.
OSTEOPOROSIS INTERNATIONAL (2004)
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis
R Lindsay et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
RM Neer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate
RS Rittmaster et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2000)
分享论文
